Cardiovascular Revascularization Medicine
Volume 9, Issue 3 , Pages 156-165 , July 2008

Association between C-reactive protein and angiographic restenosis after bare metal stents: an updated and comprehensive meta-analysis of 2747 patients

Received 4 October 2007 ,Revised 4 January 2008 ,Accepted 18 January 2008.

References 

  1. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994;331:496–501
  2. Serruys PW, De Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331:489–495
  3. Erbel R, Haude M, Hopp HW, Franzen D, Rupprecht HJ, Heublein B, et al. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group. N Engl J Med. 1998;339:1672–1678
  4. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773–1780
  5. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–1323
  6. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet. 2003;362:1093–1099
  7. Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM, et al. The Canadian study of the sirolimus eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol. 2004;43:1110–1115
  8. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003;107:38–42
  9. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003;108:788–794
  10. Stone GW, Ellis SG, Cox DA, et al. A polymer-based paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221–231
  11. Stone GW, Ellis SG, Cannon L, Hermiller J, O'Shaughnessy C, Mann JT, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA. 2005;294:1215–1223
  12. Dawkins KD, Grube E, Guagliumi G, Banning AP, Zmudka K, Colombo A, et al. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation. 2005;112:3306–3313
  13. Maisel WH. Unanswered questions—drug-eluting stents and the risk of late thrombosis. N Engl J Med. 2007;356:981–984
  14. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L SCAAR Study Group. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009–1019
  15. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:989–997
  16. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998–1008
  17. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:1030–1039
  18. Kandzari DE. Drug-eluting stent thrombosis: it's never too late. Nat Clin Pract Cardiovasc Med. 2006;3:638–639
  19. Mitra AK, Agrawal DK. In stent restenosis: bane of the stent era. J Clin Pathol. 2006;59:232–239
  20. Sharif F, Daly K, Crowley J, O'Brien T. Current status of catheter- and stent-based gene therapy. Cardiovasc Res. 2004;64:208–216
  21. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol. 1998;31:224–230
  22. Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol. 2002;22:1769–1776
  23. Ashley EA, Ferrara R, King JY, Vailaya A, Kuchinsky A, He X, et al. Network analysis of human in-stent restenosis. Circulation. 2006;114:2644–2654
  24. Monraats PS, Pires NM, Agema WR, Zwinderman AH, Schepers A, De Maat MP, et al. Genetic inflammatory factors predict restenosis after percutaneous coronary interventions. Circulation. 2005;112:2417–2425
  25. Ganesh SK, Skelding KA, Mehta L, O'Neill K, Joo J, Zheng G, et al. Rationale and study design of the CardioGene Study: genomics of in-stent restenosis. Pharmacogenomics. 2004;5:952–1004
  26. Agema WR, Jukema JW, Pimstone SN, Kastelein JJ. Genetic aspects of restenosis after percutaneous coronary interventions: towards more tailored therapy. Eur Heart J. 2001;22:2058–2074
  27. Petrovic D, Peterlin B. Genetic markers of restenosis after coronary angioplasty and after stent implantation. Med Sci Monit. 2005;11:RA127–RA135
  28. Ribichini F, Steffenino G, Dellavalle A, Matullo G, Colajanni E, Camilla T, et al. Plasma activity and insertion/deletion polymorphism of angiotensin I—converting enzyme: a major risk factor and a marker of risk for coronary stent restenosis. Circulation. 1998;97:147–154
  29. Monraats PS, Rana JS, Zwinderman AH, de Maat MP, Kastelein JP, Agema WR, et al. -455G/A polymorphism and preprocedural plasma levels of fibrinogen show no association with the risk of clinical restenosis in patients with coronary stent placement. Thromb Haemost. 2005;93:564–569
  30. Monraats PS, Kurreeman FA, Pons D, Sewgobind VD, de Vries FR, Zwinderman AH, et al. Interleukin 10: a new risk marker for the development of restenosis after percutaneous coronary intervention. Genes Immun. 2007;8:44–50
  31. Tomoda H, Aoki N. Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction. Am Heart J. 2000;140:324–328
  32. Zhou YF, Csako G, Grayston JT, Wang SP, Yu ZX, Shou M, et al. Lack of association of restenosis following coronary angioplasty with elevated C-reactive protein levels or seropositivity to Chlamydia pneumoniae. Am J Cardiol. 1999;84:595–598
  33. Angioi M, Abdelmouttaleb I, Rodriguez RM, Aimone-Gastin I, Adjalla C, Gueant JL, et al. Increased C-reactive protein levels in patients with in-stent restenosis and its implications. Am J Cardiol. 2001;87:1189–1193
  34. Walter DH, Fichtlscherer S, Sellwig M, Auch-Schwelk W, Schachinger V, Zeiher AM. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol. 2001;37:839–846
  35. Walter DH, Fichtlscherer S, Britten MB, Rosin P, Auch-Schwelk W, Schachinger V, et al. Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. J Am Coll Cardiol. 2001;38:2006–2012
  36. Zairis MN, Ambrose JA, Manousakis SJ, Stefanidis AS, Papadaki OA, Bilianou HI, et al. Global Evaluation of New Events and Restenosis After Stent Implantation Study Group. The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: The Global Evaluation of New Events and Restenosis After Stent Implantation Study. J Am Coll Cardiol. 2002;40:1375–1382
  37. Dibra A, Mehilli J, Braun S, Hadamitzky M, Baum H, Dirschinger J, et al. Association between C-reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting. Am J Med. 2003;114:715–722
  38. Ijsselmuiden AJ, Serruys PW, Scholte A, Kiemeneij F, Slagboom T, vd Wieken LR, et al. Direct coronary stent implantation does not reduce the incidence of in-stent restenosis or major adverse cardiac events: six month results of a randomized trial. Eur Heart J. 2003;24:421–429
  39. Hoshida S, Nishino M, Takeda T, Tanouchi J, Yamada Y, Hori M. A persistent increase in C-reactive protein is a risk factor for restenosis in patients with stable angina who are not receiving statins. Atherosclerosis. 2004;173:285–290
  40. Rittersma SZ, de Winter RJ, Koch KT, Schotborgh CE, Bax M, Heyde GS, et al. Preprocedural C-reactive protein is not associated with angiographic restenosis or target lesion revascularization after coronary artery stent placement. Clin Chem. 2004;50:1589–1596
  41. Hong YJ, Jeong MH, Lim SY, Lee SR, Kim KH, Sohn IS, et al. Elevated preprocedural high-sensitivity C-reactive protein levels are associated with neointimal hyperplasia and restenosis development after successful coronary artery stenting. Circ J. 2005;69:1477–1483
  42. Hong YJ, Jeong MH, Lim SY, Lee SR, Hong SN, Kim KH, et al. Relation of soft plaque and elevated preprocedural high-sensitivity C-reactive protein levels to incidence of in-stent restenosis after successful coronary artery stenting. Am J Cardiol. 2006;98:341–345
  43. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation. 1999;99:855–860
  44. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994;331:417–424
  45. Biasucci LM, Liuzzo G, Colizzi C, Rizzello V. Clinical use of C-reactive protein for the prognostic stratification of patients with ischemic heart disease. Ital Heart J. 2001;2:164–171
  46. Biasucci LM, Giubilato G, Biondi-Zoccai G, Sanna T, Liuzzo G, Piro M, et al. C reactive protein is associated with malignant ventricular arrhythmias in patients with ischaemia with implantable cardioverter-defibrillator. Heart. 2006;1147–1148
  47. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med. 2006;145:21–29
  48. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?. Circulation. 2004;109:2818–2825
  49. Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation. 2004;109:1955–1959
  50. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials. 1986;7:177–188
  51. Cochrane Handbook for systematic reviews of interventions 4.2.6. (Updated September 2006.) www.cochrane.org/resources/handbook/index.htm. The Cochrane Collaboration 2006;8.5.6.2.
  52. Woolf B. On estimating the relationship between blood group and disease. Ann Human Genet. 1955;19:251–253
  53. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560
  54. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634
  55. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–1101
  56. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326:219
  57. Schwartz RS, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes D. Restenosis after balloon angioplasty: a practical proliferative model in the porcine coronary arteries. Circulation. 1990;82:2190–2200
  58. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol. 1992;19:267–274
  59. Karas SP, Gravanis MB, Santoian EC, Robinson KA, Anderberg KA, King SB. Coronary intimal proliferation after balloon injury and stenting in swine: an animal model of restenosis. J Am Coll Cardiol. 1992;20:467–474
  60. Libby P, Schwartz E, Brogi H, Tanaka H, Clinton SK. A cascade model for restenosis: a special case of atherosclerosis progression. Circulation. 1992;86(Suppl III):III-47–III-52
  61. Liuzzo G, Buffon A, Biasucci LM, Gallimore JR, Caligiuri G, Vitelli A, et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation. 1998;98:2370–2376
  62. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102:2165–2168
  63. Patel SS, Thiagarajan R, Willerson JT, Yeh ET. Inhibition of a4 integrin and ICAM-1 markedly attenuate macrophage homing to atherosclerotic plaques in ApoE-deficient mice. Circulation. 1998;97:75–81
  64. Liuzzo G, Santamaria M, Biasucci LM, Narducci M, Colafrancesco V, Porto A, et al. Persistent activation of nuclear factor kappa-B signaling pathway in patients with unstable angina and elevated levels of C-reactive protein evidence for a direct proinflammatory effect of azide and lipopolysaccharide-free C-reactive protein on human monocytes via nuclear factor kappa-B activation. J Am Coll Cardiol. 2007;49:185–194
  65. Pepys MB, Hawkins PN, Kahan MC, Tennent GA, Gallimore JR, Graham D, et al. Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res. 2005;97:e97–e103
  66. Park DW, Lee CW, Yun SC, Kim YH, Hong MK, Kim JJ, et al. Prognostic impact of preprocedural C-reactive protein levels on six-month angiographic and one-year clinical outcomes after drug-eluting stent implantation. Heart. 2007;93:1087–1092
  67. Versaci F, Gaspardone A, Tomai F, Ribichini F, Russo P, Proietti I, et al. Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study). J Am Coll Cardiol. 2002;40:1935–1942
  68. Meredith KG, Horne BD, Pearson RR, Maycock CA, Lappe DL, Anderson JL, et al. Comparison of effects of high (80 mg) versus low (20 mg) dose of simvastatin on C-reactive protein and lipoproteins in patients with angiographic evidence of coronary arterial narrowing. Am J Cardiol. 2007;99:149–153
  69. Hernandez TL, Capell WH, Wolfe P, Gerard LA, Eckel RH. Time course of C-reactive protein reduction with simvastatin therapy in patients with type 2 diabetes mellitus. Am J Cardiol. 2006;98:1656–1659
  70. Hanefeld M, Marx N, Pfutzner A, Baurecht W, Lubben G, Karagiannis E, et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol. 2007;49:290–297

PII: S1553-8389(08)00004-3

doi: 10.1016/j.carrev.2008.01.003

Cardiovascular Revascularization Medicine
Volume 9, Issue 3 , Pages 156-165 , July 2008

Article Tools

* Image Usage & Resolution